Home
|
Contact Us
|
Bookmark
HEPATITIS
HBV
HCV
HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE)
HEPATORENAL SYNDROME (HRS)
PRIMARY BILIARY CHOLANGITIS (PBC)
THROMBOCYTOPENIA
NASH
HCC
LiverQ Academy
About CLDF
Board of Trustees
Board of Advisors/Faculty
2020 GI Fellow Board of Advisors
CLDF Committees
Centers of Educational Expertise
Live CME Events
Webcasts
Slide Library
Abstract Library
CLDF 2019 Year in Review
Conference Highlights
Drug & Device Development
Available Topics
11-24-2014
Obeticholic acid promising against NASH liver damage
11-20-2014
Drug spending tops $1 trln on hepatitis C, cancer therapies -study
11-11-2014
Interferon-free regimen works against HCV in liver recipients
11-11-2014
AbbVie, Enanta drug shows potential in hep C genotype 4 patients
11-10-2014
INSIGHT-After hep C cure, companies target next big liver disease market
11-03-2014
Sofosbuvir-ledipasvir effective for relapsed HCV-1
09-30-2014
France uses tax to put pressure on hepatitis C drug prices
09-22-2014
Smartphone app may allow parents to screen newborns for jaundice
09-17-2014
Gilead's pancreas cancer drug fails mid-stage study
09-03-2014
Triptolide nanoformulation targets liver cancer cells
08-27-2014
ANALYSIS-InterMune drug may offer big upside to Roche if aimed at liver
08-15-2014
Achillion's hepatitis C drug cures all patients in mid-stage trial
08-12-2014
Intercept drug for non-alcoholic steatohepatitis found effective
08-06-2014
High HCV response rates with daclatasvir/asunaprevir: phase III data
07-23-2014
Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter
07-16-2014
Lanreotide slows progression of neuroendocrine tumors
07-11-2014
Senators ask Gilead to explain cost of Sovaldi hepatitis drug
07-07-2014
Japan approves all-oral hepatitis C dual drug regimen
06-17-2014
AbbVie all-oral hepatitis C therapy gets rapid EU review
06-13-2014
AbbVie says hepatitis C regimen gets nod for FDA priority review
06-11-2014
Lilly's Cyramza fails in liver cancer trial
05-16-2014
Drug for alpha-1 antitrypsin deficiency fails key trial
04-22-2014
Drug combination shows more efficacy against hepatitis C
04-14-2014
Drug for primary biliary cirrhosis proves highly effective in study
04-11-2014
Doctors welcome hepatitis C drug rivals
04-10-2014
Bristol-Myers hepatitis C treatment cures up to 90%: study
03-20-2014
Geron says FDA halts patient enrollment in another cancer trial
03-17-2014
Primary biliary cirrhosis drug effective in third late-stage trial
03-11-2014
Bayer's Nexavar misses target in liver cancer trial
03-04-2014
Dynavax withdraws EU marketing application for Hep B vaccine
03-04-2014
Panel favors continuation of tivantinib study for liver cancer
03-04-2014
Drug for nonalcoholic steatosis meets main goal in study
12-18-2013
Stellar hepatitis C data puts Gilead farther ahead of pack
12-10-2013
AbbVie says most in hepatitis C study show improvement
HEPATITIS
HBV
HCV
HDV
HCC
Slide Library
Abstract Library
HE
Webcasts
Slide Library
Abstract Library
HRS
Webcasts
Slide Library
Abstract Library
NASH
Webcasts
Slide Library
Abstract Library
PBC
Webcasts
Slide Library
Abstract Library
THROMBOCYTOPENIA
Webcasts
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2021 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation
terms of use
and
privacy statement
.